CTLA4 and neoplasm: A study by Lesterhuis et al. [38] demonstrated that a concurrent schedule of gemcitabine in combination with CTLA-4 blockade in two murine tumor models yields synergistic effects resulting in the induction of a potent antitumor immune response, which confirms our observations described in this manuscript.